Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabigerol for Post Operative Recovery After Radical Cystectomy
NCT07577999Phase 1Not yet recruiting
- Sponsor
- Stanford University
- Start
- Jul 2027
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cannabigerol in bladder cancer, sponsored by Stanford University. Primary endpoint: Incidence of Grade >=2 Adverse Events and Dose-Limiting Toxicities at 1 month. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
cannabigerol
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT07577999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577999.